Clinical trial
Lenalidomide for Patients With Myelofibrosis (MF)
NCT00352794 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00352794 |
|---|---|
| Title | Lenalidomide for Patients With Myelofibrosis (MF) |
| Official title | Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelofibrosis |
| Intervention type | Drug |
| Interventions | Lenalidomide, Prednisone |
| Enrollment | 40 |
| Start date | Jul 7, 2006 |
| Primary completion | Mar 8, 2018 |
| Completion | Mar 8, 2018 |
| First posted | Jul 17, 2006 |
| Last update posted | Jul 23, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: